CareLit · DOI-Nachweis · Klinische Pädiatrie
In-vitro and in-vivo effects of Cilengitide in Glioblastoma models
DOI 10.1055/s-0033-1353452
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Schubert, C Mullins, S van Gool, L Vandenberk, M Linnebacher, CF Classen
ZeitschriftKlinische Pädiatrie
Ausgabe11/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Glioblastoma multiforme still has a very poor prognosis even with today's multimodal therapy of resection followed by radio-chemotherapy with Temozolomide. Among numerous new antitumor compounds currently under investigation, the integrin inhibitor Cilengitide has reached phase II studies, e.g. the German pediatric glioblastoma relapse study CilMetro. Materials and Methods: At our institution we establ…
Zitieren
Zitierempfehlung
J Schubert, C Mullins, S van Gool, L Vandenberk, M Linnebacher, CF Classen (2013) In-vitro and in-vivo effects of Cilengitide in Glioblastoma models. Klinische Pädiatrie (11). https://doi.org/10.1055/s-0033-1353452
Mit CareLit weiterarbeiten